Introduction to Pharmacokinetics

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion Introduction Pharmacokinetics is the study of how the body processes drugs over time. Once a drug enters the body, it follows a predictable journey: it is absorbed into the bloodstream, distributed to various tissues and organs, metabolized (chemically transformed), and finally excreted (eliminated). Understanding these four processes—collectively remembered as ADME—is essential for predicting how a drug will behave in the body, determining appropriate doses, and avoiding harmful side effects. Absorption: Getting the Drug Into the Bloodstream Routes of Administration The route by which a drug enters the body fundamentally affects how quickly and completely it reaches the systemic circulation (the bloodstream accessible to the entire body). Oral administration is the most common and convenient route. When a drug is taken by mouth, it travels to the gastrointestinal tract where it must cross the intestinal wall to enter the bloodstream. This process is called absorption. Intravenous (IV) administration bypasses absorption entirely by injecting the drug directly into a vein. This provides 100% bioavailability—meaning the entire administered dose reaches the systemic circulation. However, IV administration provides no buffer, so effects appear immediately and must be carefully monitored. Topical administration applies the drug to the skin or mucous membranes (such as under the tongue). This typically results in limited systemic absorption; the drug may act locally or be absorbed slowly over time. Subcutaneous and intramuscular administration place the drug into tissue just below the skin or into muscle, respectively. These routes fall between oral and IV in terms of speed and completeness of absorption. Inhalation delivers drugs directly to the lungs, allowing rapid absorption through a large surface area. Factors Influencing Absorption Several drug properties and physiological conditions determine whether a drug will be effectively absorbed from the gastrointestinal tract. Chemical properties of the drug: Water-solubility enhances a drug's ability to dissolve in gastrointestinal fluids and cross the intestinal membrane. Drugs must strike a balance—they need enough water solubility to dissolve, but also some lipophilic (fat-loving) character to cross cell membranes. Chemical stability in gastric acid is critical. The acidic environment of the stomach can break down or inactivate certain drugs before they reach the small intestine. Drugs that are unstable in acid must be formulated specially (such as in enteric-coated tablets that dissolve only in the more neutral environment of the small intestine). Physiological factors: Presence of food in the stomach can delay gastric emptying, slowing how quickly the drug reaches the small intestine where most absorption occurs. Food may also bind to the drug or compete for absorption, reducing the amount absorbed. Gastrointestinal pH changes along the digestive tract (very acidic in the stomach, neutral to slightly alkaline in the small intestine). This pH gradient influences whether a drug becomes ionized (electrically charged) or remains non-ionized (uncharged). Ionized drugs cannot cross lipid membranes as easily as non-ionized drugs, so pH directly affects how much drug can be absorbed. Gastrointestinal motility (the coordinated muscle contractions that move food through the digestive tract) controls how long a drug stays in any one location. Faster motility means less time for absorption; slower motility allows more complete absorption. Conditions that slow motility (such as certain medications) can paradoxically improve absorption by allowing more contact time. Oral Absorption Specifics: The Small Intestine and First-Pass Metabolism Although drugs can be absorbed from the stomach, the small intestine is where the majority of oral drug absorption occurs. This is because the small intestine has an enormous surface area (due to folds, villi, and microvilli) and a rich blood supply, making it ideal for absorption. After crossing the intestinal membrane, an orally absorbed drug enters the portal blood, which flows directly to the liver before reaching the general circulation. In the liver, the drug may be metabolized (chemically altered or even inactivated) before it ever reaches the rest of the body. This phenomenon is called first-pass metabolism or presystemic metabolism, and it can substantially reduce the amount of active drug that reaches the systemic circulation. Bioavailability is defined as the fraction of an administered dose that reaches the systemic circulation in unchanged form. For intravenous drugs, bioavailability is always 100%. For oral drugs, bioavailability is typically much lower because of incomplete absorption and first-pass metabolism. For example, if a drug has an oral bioavailability of 20%, only 20% of the oral dose reaches the general circulation; the other 80% is either not absorbed or is metabolized in the liver. Clinical Implications of Absorption Understanding absorption has direct consequences for clinical practice. Low bioavailability requires higher oral doses to achieve therapeutic plasma concentrations. This is why the oral dose of a drug is often much higher than its IV dose. Rapid absorption produces a quick onset of action (which may be desirable) but can also generate high peak concentrations that may cause toxicity or side effects. Slow absorption produces a more gradual rise in drug concentration, leading to lower peak levels and potentially a more sustained therapeutic effect with fewer toxicity concerns. Distribution: Where the Drug Goes Body Compartments and Blood Flow Once a drug enters the bloodstream, it does not stay there uniformly. Instead, it distributes into three main compartments: Plasma (the liquid portion of blood) Interstitial fluid (the fluid bathing all cells outside the blood vessels) Intracellular fluid (the fluid inside cells) The rate at which a drug enters each compartment depends largely on organ perfusion—the blood flow to that organ. Organs with high blood flow, such as the liver, kidneys, heart, and brain, receive drug very quickly. Poorly perfused tissues, such as fat or bone, receive drug more slowly. Membrane Permeability: Lipophilic vs. Hydrophilic Drugs Lipophilic (fat-loving) drugs readily dissolve in and cross cell membranes. These drugs distribute widely throughout the body and accumulate in fatty tissue. Because fat is poorly perfused (receives little blood flow), lipophilic drugs can remain stored in fat for extended periods, slowly releasing back into the bloodstream. Hydrophilic (water-loving) drugs are polar and charged, making it difficult for them to cross lipid membranes. These drugs tend to remain within the vascular compartment and interstitial fluid unless active transport mechanisms carry them across membranes. This limits their distribution to tissues with active uptake mechanisms. Plasma Protein Binding Many drugs bind reversibly to plasma proteins, particularly albumin, the most abundant plasma protein. When a drug is protein-bound, it is sequestered and unavailable to leave the bloodstream or interact with receptors in tissues. Only the free (unbound) fraction of a drug can distribute to tissues and exert therapeutic effects. Highly protein-bound drugs (those binding >90% to albumin) often remain confined to the vascular space and have limited tissue penetration. The protein-bound portion acts as a reservoir, continuously releasing drug as the free concentration declines. This has important clinical implications: if another drug displaces a highly protein-bound drug from albumin, the free concentration of the first drug suddenly increases, potentially causing toxicity. Factors Modifying Distribution Several patient-specific factors alter how drugs distribute. Body composition changes with age. Elderly patients typically have increased body fat and decreased total body water. Because of this, lipophilic drugs have a larger apparent volume of distribution (discussed later) in elderly patients, potentially leading to slower elimination and longer half-lives. Low plasma protein levels (hypoalbuminemia), seen in liver disease, severe malnutrition, and kidney disease, mean less protein available for binding. This increases the free fraction of protein-bound drugs, potentially raising plasma concentrations to toxic levels even with normal dosing. Co-administered drugs can compete for the same protein-binding sites. If two highly protein-bound drugs are given together, one may displace the other, acutely raising the free concentration of the displaced drug. Metabolism: Chemically Transforming the Drug Primary Site of Metabolism The liver is the principal organ of drug metabolism. Specialized enzymatic systems in liver cells, particularly the cytochrome P450 (CYP450) family of enzymes, catalyze three major types of reactions: Oxidation (the most common reaction) Reduction Hydrolysis (breaking bonds) These reactions chemically modify the drug molecule, usually preparing it for elimination. Purpose of Metabolism Metabolism serves several functions, not all beneficial. Primary purpose: Increasing water solubility. Most drugs are relatively lipophilic, which allows them to cross membranes and reach their targets, but lipophilic drugs are reabsorbed in the kidney and are hard to eliminate. Metabolic enzymes add polar groups to drugs, making them more water-soluble and easier to excrete in urine. Secondary effects: Metabolism can produce active metabolites that themselves contribute to the therapeutic effect (sometimes desirable) or toxic metabolites that cause adverse reactions (undesirable). Factors Influencing Metabolic Rate Genetic polymorphisms in cytochrome P450 enzymes create inter-individual differences in drug clearance. Some people are "fast metabolizers" (with more active enzyme variants) and others are "slow metabolizers" (with less active variants). These genetic differences can dramatically affect drug efficacy and toxicity. Enzyme-inducing agents increase the activity of metabolic enzymes. Chronic alcohol use, smoking, and certain medications (like phenytoin and rifampin) induce CYP450 enzymes, accelerating the metabolism and clearance of co-administered drugs. This can lower plasma concentrations of co-administered drugs below therapeutic levels. Enzyme-inhibiting agents decrease metabolic activity. Drugs like ketoconazole, erythromycin, and grapefruit juice inhibit CYP450 enzymes, slowing the clearance of co-administered drugs and potentially leading to toxic accumulation. Clinical Consequences of Metabolism Rapid metabolism requires higher or more frequent doses to maintain therapeutic concentrations. Fast metabolizers may need 50–100% higher doses than average patients. Slow metabolism extends the drug's half-life, often requiring dose reduction to prevent toxicity. Slow metabolizers accumulate drug more readily. Hepatic impairment diminishes the liver's metabolic capacity. Patients with cirrhosis or other liver disease have reduced clearance of hepatically metabolized drugs and require dose adjustments. Excretion: Eliminating the Drug Renal Excretion Mechanisms The kidneys are the body's primary excretory organ and eliminate drugs and their metabolites. Three distinct renal mechanisms operate: Glomerular filtration occurs in the kidney's filtering unit (the glomerulus). Small, unbound drug molecules are passively filtered from blood into the urine. Protein-bound drugs cannot be filtered. Tubular secretion actively transports drug molecules from the blood into the renal tubules. This active process can eliminate bound and unbound drug alike, making it more effective at clearing drug than filtration alone. Tubular reabsorption occurs when drug molecules in the tubular fluid are reabsorbed back into the bloodstream. This is particularly important for lipophilic, non-ionized drugs, which readily cross the tubular membrane. Drugs that are ionized or hydrophilic are less likely to be reabsorbed and are more completely eliminated in urine. These three mechanisms operate simultaneously, and the net renal excretion reflects the balance among them. Non-Renal Excretion Routes Biliary excretion transports drug molecules into bile, which is stored in the gallbladder and emptied into the small intestine. The drug is then eliminated in feces. However, some drugs excreted in bile are reabsorbed in the small intestine, returned to the liver via the portal blood, and recycled. This recycling is called enterohepatic recirculation and can extend a drug's half-life by returning it to the systemic circulation. <extrainfo> Other minor routes of excretion include the lungs (useful for volatile substances), skin, and other body fluids, but these are generally minor contributors to total drug elimination. </extrainfo> Factors Affecting Excretion Renal function declines with age and disease. Elderly patients often have reduced glomerular filtration rates, and patients with kidney disease have impaired clearance. Renally eliminated drugs accumulate in patients with renal impairment. Urine pH influences drug ionization and therefore tubular reabsorption. In acidic urine, weak bases become ionized and are eliminated more completely; weak acids are reabsorbed. The opposite occurs in alkaline urine. This principle is sometimes exploited therapeutically—for example, alkalinizing the urine can increase elimination of certain drug overdoses. Competition for renal transporters can occur when multiple drugs rely on the same active secretion mechanism. One drug may inhibit the secretion of another, reducing clearance and potentially causing accumulation. Clinical Implications of Excretion Impaired renal excretion necessitates dose adjustment to prevent drug accumulation and toxicity. Dose adjustments are guided by measurements of renal function (such as creatinine clearance) and, when available, therapeutic drug monitoring. Pharmacokinetic Parameters: Quantifying Drug Behavior Three key parameters summarize the body's handling of a drug and allow predictions about dosing and accumulation. Half-Life ($t{1/2}$) Half-life is the time required for the plasma concentration of a drug to decrease by 50%. For example, if a drug has a concentration of 100 mg/L at time zero and a half-life of 6 hours, the concentration will be 50 mg/L at 6 hours, 25 mg/L at 12 hours, and 12.5 mg/L at 18 hours. Half-life is independent of the dose—it is determined by the drug's properties and the body's ability to eliminate it. Half-life is crucial for predicting dosing intervals. A rule of thumb: after approximately 5 half-lives, a drug is considered to have been essentially eliminated from the body. Additionally, at steady state (after repeated dosing), drug accumulates until elimination rate equals the dosing rate, which typically takes 3–5 half-lives to achieve. Clearance ($Cl$) Clearance is the volume of plasma from which drug is completely removed per unit time, expressed in mL/min or L/hour. Clearance reflects the combined efficiency of all elimination processes—metabolism plus all routes of excretion. High clearance means rapid drug removal; low clearance means slow removal. Clearance is proportional to dose: if you double the dose, you double the amount eliminated per unit time (in first-order kinetics, the most common situation). However, clearance itself remains constant regardless of dose. Volume of Distribution ($Vd$) Volume of distribution is a theoretical volume that relates the total amount of drug in the body to the concentration in plasma. Mathematically, $Vd = \frac{\text{Total amount of drug in body}}{\text{Plasma concentration}}$. $Vd$ is not a real physiologic volume; it is a mathematical construct. However, it is highly useful for understanding drug behavior. A large $Vd$ (larger than total body volume) indicates that the drug has extensively distributed into tissues—it has left the vascular compartment. Lipophilic drugs and drugs that bind to tissue proteins typically have large $Vd$ values. A small $Vd$ (close to plasma volume, 3.5 L) indicates that the drug remains primarily in the vascular space, largely confined by protein binding or hydrophilicity. $Vd$ directly affects how much loading dose is needed to rapidly achieve a target plasma concentration (see Clinical Application section below). Relationship Between Parameters These three parameters are related by a fundamental equation: $$t{1/2} = \frac{0.693 \times Vd}{Cl}$$ This equation reveals that: Increasing clearance shortens half-life. If a drug is metabolized or excreted more efficiently, it leaves the body faster. Increasing volume of distribution lengthens half-life. If a drug distributes widely into tissue, it takes longer to eliminate because much of the drug is not in plasma where it can be excreted or metabolized. This relationship is powerful: if you know any two parameters, you can calculate the third. The image above shows a concentration-time curve illustrating how a drug's concentration rises to a peak ($C{max}$) following administration, then declines. The shaded areas under the curve represent the total drug exposure over time, quantified as Area Under the Curve (AUC). Repeated dosing produces multiple peaks and troughs, illustrating concepts like dosing intervals and steady-state concentrations discussed in the next section. Clinical Application of Pharmacokinetics Designing Dosing Regimens Pharmacokinetic principles directly guide dosing decisions. Dosing intervals are chosen based on the drug's half-life. A common goal is to maintain plasma concentrations within a therapeutic window—the range where the drug is effective but not toxic. Dosing intervals are often set to approximately one half-life (when the previous dose has declined to roughly 50% of its initial concentration), ensuring that concentrations remain relatively stable between doses. Loading doses are calculated to rapidly achieve the target plasma concentration without waiting for accumulation over multiple doses. The loading dose depends on the volume of distribution: $$\text{Loading dose} = Vd \times \text{Target plasma concentration}$$ For example, if a drug has a $Vd$ of 50 L and you want to achieve a plasma concentration of 10 mg/L, the loading dose would be 500 mg. Without a loading dose, it would take 3–5 half-lives to reach that concentration. Maintenance doses are derived from clearance and are given to replace the amount of drug eliminated per unit time: $$\text{Maintenance dose} = Cl \times \text{Target plasma concentration} \times \text{Dosing interval}$$ This ensures that the amount given per dose matches the amount eliminated, preventing accumulation or decline in plasma concentration between doses. Impact of Age and Disease Elderly patients present special pharmacokinetic challenges. They typically have: Reduced renal function, decreasing clearance of renally eliminated drugs Altered body composition (increased fat, decreased water), enlarging the apparent $Vd$ for lipophilic drugs and reducing it for hydrophilic drugs Reduced plasma proteins, increasing the free fraction of protein-bound drugs These changes often necessitate lower maintenance doses and longer dosing intervals. Hepatic disease diminishes the liver's metabolic capacity, reducing clearance of hepatically metabolized drugs. Patients with cirrhosis or severe hepatitis often require substantial dose reductions to avoid toxicity. Renal disease impairs glomerular filtration and tubular secretion, reducing clearance of renally eliminated drugs. Dose adjustments are based on the degree of renal impairment, often estimated using creatinine clearance. Drug-Drug Interactions Involving Metabolism and Elimination Enzyme induction occurs when one drug increases the metabolism of another. For example, if a patient taking warfarin (a blood thinner) begins taking rifampin (an antibiotic), rifampin induces warfarin metabolism, increasing warfarin clearance. The warfarin concentration falls, reducing its anticoagulant effect. If warfarin is not dose-increased, bleeding risk decreases dangerously. Enzyme inhibition occurs when one drug decreases the metabolism of another. Ketoconazole inhibits the metabolism of many drugs, including certain statins. This can raise plasma concentrations of the statin to toxic levels, risking muscle damage (rhabdomyolysis). Competition for renal secretion can reduce the clearance of one drug in the presence of another. Classic examples include probenecid, which inhibits the tubular secretion of penicillin, thereby prolonging penicillin's half-life. Monitoring and Dose Adjustment Therapeutic drug monitoring involves measuring plasma concentrations of drugs with narrow therapeutic windows (drugs where therapeutic and toxic concentrations are close). Examples include digoxin, phenytoin, vancomycin, and aminoglycosides. Plasma concentrations should be drawn at appropriate times to reflect the patient's true steady-state (usually after 3–5 half-lives) and timing relative to the dose (trough concentrations—just before a dose—are often most relevant). Dose adjustments are made based on: Observed plasma concentrations relative to target range Changes in patient factors (aging, development of renal disease) Addition or removal of interacting drugs Changes in adherence or bioavailability Regular reassessment of renal and hepatic function guides dose optimization, particularly in patients with changing clinical status.